Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18811782 | 0.74 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL21076444 | 0.73 | ESR1 (0.42) | ESR1ESR2 | |
| SCHEMBL12120613 | 0.72 | GABRA1 (0.33) | ESR1 | |
| SCHEMBL22895111 | 0.71 | NR3C2 (0.41) | ESR1ESR2 | |
| SCHEMBL21076611 | 0.71 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL23758345 | 0.70 | ALDH1A1 (0.34) | ESR1ESR2 | |
| SCHEMBL18763535 | 0.70 | LMNA (0.42) | ESR1ESR2 | |
| SCHEMBL18683654 | 0.69 | NR3C2 (0.46) | ESR1ESR2 | |
| SCHEMBL23758353 | 0.69 | CYP3A4 (0.36) | ESR1ESR2 | |
| SCHEMBL19831132 | 0.69 | GPR55 (0.35) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | ESR1 2273/4885ESR2 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.